FDA warned The Medicine Shoppe Pharmacy in Port Charlotte, Florida, over insanitary compounding conditions, vermin, and drugs made without valid prescriptions.
What happened
FDA investigators inspected the pharmacy from March 9 to March 16, 2020, and found dead ants on the production floor and dead cockroaches in a drawer next to the hood where drugs were made, plus stained equipment and damaged ceiling tiles. Investigators also found the firm compounded some drugs without valid prescriptions for individually identified patients. The firm recalled all of its drug products within expiry in March and April 2020 and said it no longer makes sterile products.
What FDA found
The firm did not keep its buildings clean and free of insects and other pests.
21 CFR 211.56(a)The firm did not clean and maintain its equipment and work surfaces well enough to prevent contamination.
21 CFR 211.67(a)Ceiling tiles in the production area were unsealed, cracked and stained, including a brown water stain.
21 CFR 211.56(a)Hazardous drugs were handled without adequate containment, separation or cleaning of surfaces and utensils, risking cross-contamination.
21 U.S.C. § 351(a)(2)(A)Some drugs were compounded without valid prescriptions for individually identified patients, so they lost the exemption for compounded drugs.
Section 503A of the FDCA [21 U.S.C. § 353a]The drugs' labeling lacked adequate directions for use because the conditions they treat cannot be safely self-diagnosed and treated by a layperson.
Section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)]
What FDA wants
FDA asks the firm to write within 15 working days describing the specific steps taken to correct the violations, with supporting documentation such as cleaning logs and pest control records. The firm must also notify FDA 15 working days before resuming production of any sterile drugs.
Who should pay attention
- pharmacies and prescribers that sent prescriptions to this compounding pharmacy
- distributors and buyers that purchased its compounded drugs
- other compounding pharmacies that handle hazardous drugs or sterile products
This is a summary. Read the original letter on fda.gov.